Clinical Trial Update: A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating LY293111 in combination with gemcitabine versus gemcitabine with placebo for pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LY293111

Snippet

Sponsor: Eli Lilly and Company | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED